- Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system.
- The company’s AditxtScore(TM) for COVID-19 generates an AditxtScore(TM), which offers a detailed profile of a person’s immune response for SARS-CoV-2, allowing consumers and their physicians to understand, manage, and monitor their level of immune response to the virus, thus allowing them to make informed health decisions
- Aditxt’s platform is initially focusing on SARS-CoV-2, the virus that causes COVID-19, in recognition of the importance of immune monitoring and profiling in determining the course of action related to the virus.
Though the COVID-19 pandemic is now in its third year, as noted in a recent Scientific American article (https://ibn.fm/owGS8), scientists are still unsure whether there is a measure that could tell if people are protected from the virus. Still, different measures, collectively known as “correlates of protection,” define the immune response that a vaccine or viral infection would have to trigger to protect an individual from future infection. Two of these measures, neutralizing antibodies and T cells, are instrumental in immune profiling, a process that seeks to identify a person’s specific immune responses to the virus.
And as a 2021 journal article discussing immune profiling of COVID-19 writes: “Variability in the host immune response is likely to play a major role in determining the course of SARS-CoV-2 infection. Given this, there is a need to apply immune profiling to better understand the interaction of this virus with the…
NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.